Intas Partners IntegriMedical to Introduce Needle-Free Injections for IVF and Gynaecology in India

Under the agreement, Intas will have exclusive rights to use the technology in these therapy areas, marking its formal entry into needle-free drug delivery within reproductive healthcare.

Intas Pharmaceuticals has entered into an exclusive agreement with IntegriMedical to introduce a needle-free injection system for use in IVF and gynaecology treatments across India.

Under the agreement, Intas will have exclusive rights to use the technology in these therapy areas, marking its formal entry into needle-free drug delivery within reproductive healthcare.

IntegriMedical is the developer of India’s needle-free injection system, which delivers medication through a high-pressure jet stream mechanism. The system administers drugs via a micro-orifice in the skin, eliminating the need for conventional needles. According to the companies, the technology is designed to reduce tissue impact, prevent medication pooling, and lower the risk of cross-contamination.

As part of the agreement, Intas will introduce IVF and gynaecology therapies using the needle-free system across the country. The rollout will involve deployment across IVF clinics and gynaecology centres, with a focus on integrating the technology into existing treatment protocols. The collaboration centres on changes in drug delivery methods and the treatment experience in reproductive care.

India conducts an estimated 300,000 to 350,000 IVF cycles annually, a figure projected to rise to 500,000 to 600,000 cycles by 2027. IVF treatment typically involves multiple injections over extended cycles, resulting in several million injections administered each year. The introduction of needle-free injection technology into IVF workflows is expected to influence how medications are delivered during these procedures.

The collaboration also aims to address injection-related discomfort and anxiety, factors commonly associated with long-term injectable therapies. By using IntegriMedical’s drug delivery system, the companies plan to support treatment adherence and consistency across IVF and gynaecology care pathways.

Commenting on the agreement, Sarvesh Mutha, Managing Director of IntegriMedical, said the partnership enables the application of needle-free injection technology in large-scale clinical settings within reproductive medicine.

Durga P Satapathy, Executive Vice President at Intas, said the initiative focuses on introducing alternative drug delivery options for IVF and gynaecology patients in India.

The agreement brings together Intas Pharmaceuticals and IntegriMedical to deploy needle-free injection technology specifically for IVF and gynaecology treatments, with exclusivity limited to these therapeutic areas within the Indian market.

Stay tuned for more such updates on Digital Health News